Blog Article
Regulatory approval is supposed to be the moment everything accelerates. CE Mark secured. FDA clearance granted. Years of development work have finally been validated. And then, almost immediately, a new problem surfaces: the people needed to sustain that approval, scale the quality system, and support commercial launch simply are not there.
The RA/QA talent shortage in MedTech is not a new conversation. But it is getting harder to ignore.
Approval creates demand that the market cannot absorb
Every regulatory milestone generates an immediate hiring requirement: Quality Management System ownership, post-market surveillance, MDR or FDA compliance, clinical evaluation reporting. These are not roles that can sit vacant while a search runs its course. For smaller MedTech companies in particular, a single gap in the compliance function can delay a commercial launch or create material risk with a notified body.
The problem is that the pipeline of experienced RA/QA professionals has not kept pace with the volume of approvals. MedTech Europe and industry analysts have flagged this for years. The MDR transition alone accelerated demand across Europe faster than training programs or lateral moves could realistically supply it.
Why these roles are harder to fill than they look
RA/QA is a discipline where regulatory experience is highly context-specific. Someone with a strong FDA background may need significant ramp time to operate effectively under MDR. A QA leader who has built systems inside a large corporate may struggle with the ambiguity of a 30-person startup. Functional competence and contextual fit are both non-negotiable, which makes the search genuinely difficult, not just time-consuming.
There is also a visibility problem. The most experienced compliance professionals are rarely active job seekers. They are embedded in companies that depend on them, often invisible to keyword-based searches, and unlikely to respond to generic outreach.
What companies consistently underestimate
The hire is rarely planned far enough in advance. Regulatory timelines are uncertain by nature, so headcount planning for post-approval roles tends to happen late. By the time approval lands, the urgency is immediate but the search has not started. That gap, between when the need becomes real and when the right person is in seat, is where commercial momentum is lost.
Companies that manage this well tend to start the conversation earlier, often before approval is confirmed, and work with search partners who have genuine depth in the compliance function rather than treating it as a standard commercial role.
Guided Solutions has placed RA/QA and regulatory leadership across more than 630 MedTech clients over 26 years of exclusive industry focus. If your compliance function needs to scale alongside your regulatory milestones, the conversation is worth having early.
